Annovis Bio, Inc. (ANVS)
NYSE: ANVS · Real-Time Price · USD
1.720
+0.070 (4.24%)
At close: Jun 26, 2026, 4:00 PM EDT
1.730
+0.010 (0.58%)
Pre-market: Jun 29, 2026, 7:11 AM EDT
Company Description
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States.
The company’s lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer’s disease, as well as in open-label phase 3 to treat parkinson’s disease.
It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer’s disease and dementia.
Annovis Bio, Inc. was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.
Annovis Bio, Inc.
| Country | United States |
| Founded | 2008 |
| IPO Date | Jan 29, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Maria Maccecchini |
Contact Details
Address: 101 Lindenwood Drive, Suite 225 Malvern, Pennsylvania 19355 United States | |
| Phone | 484 875 3192 |
| Website | annovisbio.com |
Stock Details
| Ticker Symbol | ANVS |
| Exchange | NYSE |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $6.00 |
| CIK Code | 0001477845 |
| CUSIP Number | 03615A108 |
| ISIN Number | US03615A1088 |
| Employer ID | 26-2540421 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Maria L. Maccecchini Ph.D. | Founder, Acting Chief Financial Officer, Chief Executive Officer, President and Executive Director |
| Dr. Cheng Fang Ph.D. | Senior Vice President of Research and Development |
| Eve M. Damiano M.S., RAC | Senior Vice President of Regulatory Operations |
| Blake Jensen M.B.A. | Head of Quality |
| Hilda Maibach | Senior Vice President of Statistics |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 17, 2026 | 8-K | Current Report |
| May 20, 2026 | 8-K | Current Report |
| May 20, 2026 | 424B5 | Filing |
| May 19, 2026 | 424B5 | Filing |
| May 15, 2026 | 10-Q | Quarterly Report |
| May 15, 2026 | 8-K | Current Report |
| Apr 30, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 30, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 10, 2026 | 8-K | Current Report |
| Apr 9, 2026 | 424B5 | Filing |